DBV Technologies Appoints Daniel Tassé as Chief Executive Officer - Seite 3

Daniel is currently a member of the Board of Directors of Indivior PLC (London Stock Exchange: INDV), where he is the Lead Independent Director, a member of the Audit Committee and a member of the Remuneration Committee; of Bellerophon Therapeutics (NASDAQ: BLPH) where he is a member of the Audit Committee and the Compensation Committee; of Regenxbio (NASDAQ: RGNX) where he is a member of the Compensation Committee; and of HLS Therapeutics (Toronto Stock Exchange: HLSV) where he is a member of the Audit Committee.

He holds a B.Sc. in Biochemistry from Université de Montréal and is fluent in both French and English.

About DBV Technologies 

DBV Technologies is developing Viaskin, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut and the EPIT platform and the anticipate benefits of Mr. Tassé becoming the Company's Chief Executive Officer. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as those associated with management transitions. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2017 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.